Jason A. Beliakoff, Ph.D.
Affiliations: | 2003 | University of Arizona, Tucson, AZ |
Area:
Oncology, Cell Biology, Molecular BiologyGoogle:
"Jason Beliakoff"Parents
Sign in to add mentor| Luke J. Whitesell | grad student | 2003 | University of Arizona | |
| (Regulation of estrogen receptor function by molecular chaperones.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Beliakoff J, Lee J, Ueno H, et al. (2008) The PIAS-like protein Zimp10 is essential for embryonic viability and proper vascular development. Molecular and Cellular Biology. 28: 282-92 |
| Lee J, Beliakoff J, Sun Z. (2007) The novel PIAS-like protein hZimp10 is a transcriptional co-activator of the p53 tumor suppressor. Nucleic Acids Research. 35: 4523-34 |
| Li TH, Zhao H, Peng Y, et al. (2007) A promoting role of androgen receptor in androgen-sensitive and -insensitive prostate cancer cells. Nucleic Acids Research. 35: 2767-76 |
| Beliakoff J, Sun Z. (2006) Zimp7 and Zimp10, two novel PIAS-like proteins, function as androgen receptor coregulators Nuclear Receptor Signaling. 4 |
| Li X, Thyssen G, Beliakoff J, et al. (2006) The novel PIAS-like protein hZimp10 enhances Smad transcriptional activity. The Journal of Biological Chemistry. 281: 23748-56 |
| Jeffy BD, Hockings JK, Kemp MQ, et al. (2005) An estrogen receptor-alpha/p300 complex activates the BRCA-1 promoter at an AP-1 site that binds Jun/Fos transcription factors: repressive effects of p53 on BRCA-1 transcription. Neoplasia (New York, N.Y.). 7: 873-82 |
| Huang CY, Beliakoff J, Li X, et al. (2005) hZimp7, a novel PIAS-like protein, enhances androgen receptor-mediated transcription and interacts with SWI/SNF-like BAF complexes. Molecular Endocrinology (Baltimore, Md.). 19: 2915-29 |
| Bagatell R, Beliakoff J, David CL, et al. (2005) Hsp90 inhibitors deplete key anti-apoptotic proteins in pediatric solid tumor cells and demonstrate synergistic anticancer activity with cisplatin International Journal of Cancer. 113: 179-188 |
| Beliakoff J, Whitesell L. (2004) Hsp90: an emerging target for breast cancer therapy. Anti-Cancer Drugs. 15: 651-662 |
| Beliakoff J, Bagatell R, Paine-Murrieta G, et al. (2004) Hormone-refractory breast cancer remains sensitive to the antitumor activity of heat shock protein 90 inhibitors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 9: 4961-71 |